Medicine
Steglujan 5 mg/100 mg tablet
Steglujan 5 mg/100 mg tablet is a prescription medicine containing Ertugliflozin pidolate and Sitagliptin for oral use, marketed by Merck Sharp & Dohme, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20°C-25°C (68°F-77°F), excursions permitted between 15°C-30°C…
Key facts
- Active ingredient (INN)
- Ertugliflozin pidolate and Sitagliptin
- Brand
- Steglujan
- Strength
- 5 mg/100 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 30 tablets, 90 tablets, 500 tablets
- Marketing authorisation holder
- Merck Sharp & Dohme
- Manufacturer
- Merck Sharp & Dohme
- Origin register
- US FDA, United States
- Storage
- Store at 20°C-25°C (68°F-77°F), excursions permitted between 15°C-30°C (between 59°F-86°F). Protect from moisture. Store in a dry place.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 19 December 2017
- Identifiers
- RxCUI 1992826, 1992832, 1992835 +1DailyMed set ID c2c553d8-5a9d-4366-bf53-8bdb5a876d19NDC 0006-5367Application NDA209805
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 30 tablet, film coated in 1 bottle | 0006-5367-03 | Merck Sharp & Dohme | 19 December 2017 |
| 90 tablet, film coated in 1 bottle | 0006-5367-06 | Merck Sharp & Dohme | 19 December 2017 |
| 500 tablet, film coated in 1 bottle | 0006-5367-07 | Merck Sharp & Dohme | 19 December 2017 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Ertugliflozin pidolate and Sitagliptin
Clinical summary
Ertugliflozin pidolate and Sitagliptin is a fixed-dose combination medicine indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. MedsAcross supplies Ertugliflozin pidolate and Sitagliptin for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Ertugliflozin pidolate and SitagliptinFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- STEGLUJAN prescribing information (Merck Sharp & Dohme) · U.S. National Library of Medicine, DailyMed
Need Steglujan 5 mg/100 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.